Joon joined BBOT in January 2025 and brings more than 20 years of drug development experience in oncology across all stages of development covering various modalities. Before joining BBOT, Joon was a Global Development Team Leader at Gilead Sciences, where he was responsible for the development and execution of the strategy for Gilead assets in GI cancers and Head & Neck cancers. Prior to Gilead, Joon was Global Development Team lead at BeiGene where he oversaw pamiparib (PARPi) and ociperlimab (TIGIT) programs and was the Global Clinical Lead at AstraZeneca for Lynparza (PARPi) combinations and new opportunities. Joon spent six years at Roche-Genentech where he helped lead efforts to develop cobimetinib (MEKi) in melanoma as well as Avastin in ovarian cancer. Prior to Roche-Genentech, Joon spent eight years at Exelixis supporting discovery and development efforts across six development programs from preclinical through clinical.

Joon received his PhD in Immunology at Stanford University, and his BA at University of California, Berkeley.